RGS 371
Alternative Names: RGS-371Latest Information Update: 12 May 2022
At a glance
- Originator RNAGENE
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Macrophage stimulants; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-small cell lung cancer
Most Recent Events
- 19 Apr 2022 Preclinical trials in Non-small cell lung cancer in South Korea (Parenteral) (RNAGENE, pipeline April 2022)